Enhancement of Endocytic Uptake of HIV-1 Virions into CD4-negative Epithelial Cells by HIV-1 Gp41 Via Its Interaction with POB1

Yue,Minghong Tan,Junyi,Hong Wang,Shan,Chang Su,Qian,Shibo,Jiang,Jiwen Lu,Yinghua,Guihai Chen

DOI: https://doi.org/10.1038/cmi.2015.38

2017-01-01

Abstract:Enhancement of endocytic uptake of HIV-1 virions into CD4-negative epithelial cells by HIV-1 gp41 via its interaction with POB1

What problem does this paper attempt to address?

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

Renee Hrin,Donna L. Montgomery,Fubao Wang,Jon H. Condra,Zhiqiang An,William R. Strohl,Elisabetta Bianchi,Antonello Pessi,Joseph G. Joyce,Ying-Jie Wang

DOI: https://doi.org/10.1089/aid.2008.0129

2008-01-01

Abstract:Class 1 and class 2 fusion peptides bind to the trimeric N-terminal heptad repeat (NHR) and C-terminal heptad repeat (CHR) regions of HIV-1 envelope glycoprotein gp41, respectively, and block its intramolecular folding required for Env-mediated viral and host cell membrane fusion and subsequent viral entry. Using a combination of T-20 (class 1) and (CCIZN17)(3) (class 2), we provide evidence that these classes of fusion peptides work synergistically in an in vitro infectivity assay in inhibiting the entry of primary HIV-1 isolate 89.6 with combination indexes reaching 0.37 and 0.32 at IC(50) and IC(90), respectively. We further demonstrate a similar degree of neutralization synergy between a monoclonal antibody (MAb), D5, targeting the hydrophobic pocket region of the NHR, and 2F5, a well-characterized MAb that targets the C-terminal end of CHR and the membrane-proximal external region (MPER), providing a rational basis for developing combination vaccines targeting these two highly conserved regions of gp41.
HIV-1 Glycoprotein 41 Ectodomain Induces Activation of the CD74 Protein-Mediated Extracellular Signal-Regulated Kinase/mitogen-Activated Protein Kinase Pathway to Enhance Viral Infection.

Chang Zhou,Lu,Suiyi Tan,Shibo Jiang,Ying-Hua Chen

DOI: https://doi.org/10.1074/jbc.m111.267393

2011-01-01

Abstract:Besides mediating the viral entry process, the human immunodeficiency virus (HIV-1) envelope protein gp41 can bind to many host cell components and regulate cell functions. Using a yeast two-hybrid system, we screened a human bone marrow cDNA library and identified a novel gp41-binding protein, CD74 (the MHC class II-associated invariant chain). Here, we report possible biological effects mediated by interaction between gp41 and CD74. We found that HIV-1 gp41 could bind directly to host CD74 in HIV-1-infected cells, and the peptide 6358 derived from gp41 loop region (aa 597-611) could effectively block the gp41-CD74 interaction. As a result of this binding, recombinant soluble gp41 and gp41 peptide 6358 activated the CD74-mediated ERK/MAPK pathway and significantly enhanced HIV-1 infection in vitro. Conversely, the enhancing effect could be suppressed by the recombinant CD74 extracellular domain. These results reveal a novel mechanism underlying gp41 mediation of HIV-1 infection and replication.
The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.

Jing-He Huang,Heng-Wen Yang,Shuwen Liu,Jing Ll,Shibo Jiang,Ying-Hua Chen

DOI: https://doi.org/10.1042/bj20061275

IF: 3.766

2007-01-01

Biochemical Journal

Abstract:The HIV-1 gp41 (glycoprotein 41) core plays a critical role in fusion between the viral and target cell membranes. We previously identified a gp41 core-binding motif, HXXNPF, by screening the phage display peptide libraries. In the present study, we elucidated the mechanism of action of HXXNPF motif-containing molecules of different sizes, including the phage clone L7.8 (a selected positive phage clone), L7.8-g3p* (a 10-kDa fragment of the gene 3 protein) and JCH-4 (a peptide containing 13 residues of L7.8-g3p*), regarding their respective binding abilities to the six-helix bundle and inhibition on syncytium formation at different temperatures. We found that all of the HXXNPF motif-containing molecules could bind to the gp41 core, and that their binding sites may be located in the N-helix domain. L7.8-g3p* and JCH-4 effectively inhibited HIV-1 Env (envelope glycoprotein)-mediated syncytium formation at 37 degrees C, while the phage clone L7.8 showed no inhibition under the same conditions. However, at suboptimal temperature (31.5 degrees C), all of these HXXNPF motif-containing molecules were capable of inhibiting syncytium formation. These results suggest that these HXXNPF motif-containing molecules mainly bind to the gp41 core and stop the fusion process mediated by the fusion-active core, resulting in inhibition of HIV-1 fusion and entry. The HXXNPF motif-containing molecules may be used as probes for studying the role of the HIV-1 gp41 core in the late stage of the membrane-fusion process.
Hiv-1 gp 41 ectodomain induces activation of the cd 74-mediated erk / mapk pathway to enhance viral infection

Chang Zhou,Lu Lu,Suiyi Tan,Shibo Jiang,Ying-Hua Chen

2011-01-01

Abstract:PATHWAY TO ENHANCE VIRAL INFECTION Chang Zhou, Lu Lu , Suiyi Tan, Shibo Jiang , Ying-Hua Chen Laboratory of Immunology, School of Life Sciences; Beijing Key Laboratory for Protein Therapeutics; Protein Science Laboratory of MOE, Tsinghua University Beijing 100084, China; MOE/MOH Key Laboratory of Medical Molecular Virology, Institute of Medical Microbiology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA
Progress in the structure and function of human immunodeficiency virus type 1 gp41

YAO Qian-Qian,LV Jun,YE Rong

DOI: https://doi.org/10.3969/j.issn.1673-6184.2011.04.008

2011-01-01

Abstract:Entrance of human immunodeficiency virus type 1 (HIV-1) into cells is mediated by envelope glycoprotein (Env), which contains a receptor-binding unit, gp120, and a membrane-fusion unit, gp41. HIV-1 gp41 consists of three major functional regions: ectodomain, membrane-spanning domain (MSD) and endodomain. The ectodomain is the structural basis for membrane fusion during viral infection; the hydrophobic residues of the MSD anchor Env to the bilayer membrane; and the endodomain plays multiple functions in viral infection, replication, and assembly. The most important motifs in the endodomain are three lentivirus lytic peptides (LLP 1-3), two Tyr-contained motifs (Y712XXL and Y802W803), and a di-leucine motif (LL856/857). Additionally, the topological change of the endodomain such as those at Kennedy epitope, indicates that there are interactions among the three regions of gp41. Progress in understanding the function-structure relationship of gp41 not only improves our knowledge about replication and pathogenesis of HIV-1 but also provides some insight into the development of new antiviral drugs.
[1,2,6-Tri-o-galloyl-beta-d-glucopyranose Inhibits Gp41-Mediated HIV Envelope Fusion with Target Cell Membrane].

Wei Sun,Hong-tao Wang,Cheng-lai Xia,Shu-guang Wu,Shi-bo Jiang,Zhi-hong Jiang,Shu-wen Liu

DOI: https://doi.org/10.3321/j.issn:1673-4254.2008.07.004

2008-01-01

Abstract:OBJECTIVE:To observe the inhibitory effect of 1,2,6-Tri-O-galloyl-beta-D-glucopyranose (TGGP) from Balanophora japonica Makino on human immunodeficiency virus (HIV) entry into the host cells and explore the mechanisms.METHODS:TGGP was purified from Balanophora japonica Makino by n-hexane and ethyl acetate extraction and column chromatography. The inhibitory activity of TGGP on HIV gp41 six-helix bundle formation was measured with ELISA, N-PAGE and SE-HPLC, and the inhibitory effect of TGGP on HIV envelope grlycoprotein-induced cell-cell fusion was detected using a non-infectious cell-based assay.RESULTS:TGGP inhibited HIV gp41 six-helix bundle formation, with an IC50 of 1.37-/+0.19 microg/ml as determined by ELISA, and this activity was further confirmed by N-PAGE and SE-HPLC. TGGP at 25 microg/ml significantly inhibited syncytium formation between the effector (CHO-WT) and the target (MT-2) cells.CONCLUSION:The HIV transmembrane subunit gp41 mediates the entry of HIV into the target cells. TGGP can inhibit HIV fusion and entry into the target cells by inhibiting the formation of gp41 six-helix bundles, suggesting the potential of TGGP as a microbicide to prevent sexual transmission of HIV.
Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte.

Shuwen Liu,Shibo Jiang,Zhihua Wu,Lin Lv,Jiajie Zhang,Zhengguang Zhu,Shuguang Wu

DOI: https://doi.org/10.1016/S0024-3205(02)01939-2

IF: 6.78

2002-01-01

Life Sciences

Abstract:An increasing portion of patients with HIV infection and/or AIDS cannot use currently FDA-approved anti-HIV drugs, including the reverse transcriptase and protease inhibitors, due to the adverse effects and the emergence of drug resistance. Thus, it is essential to develop new anti-HIV agents with a target different from the HIV reverse transcriptase and protease. Using a conformation-specific monoclonal antibody NC-1, we previously established a high throughput screening assay for identification of small molecular organic compounds that disrupt the HIV-1 gp41 six-helix bundle formation, a critical step of membrane fusion between the HIV and the target cell. In the present study, we used this assay to screen for inhibitors of the gp41 six-helix bundle formation from aqueous extracts of nine Chinese medicinal herbs with antiviral activity. We found that the extracts of two herbs, Prunella vulgaris and Rhizoma cibotte, showed potent inhibitory activity. The inhibitory activity of these two herb extracts significantly decreased after they were passed through polyamide resin mini-columns, which are able to bind polyphenols including tannin, an HIV-1 inhibitor with multiple mechanisms of action. The bound polyphenols were eluted from the polyamide columns and also showed potent inhibitory activity on the gp41 six-helix bundle formation. Tannin purchased from different commercial sources inhibited the gp41 six-helix bundle formation in a manner similar to the polyphenols isolated from the herb extracts. These results suggest that tannin may be one of major inhibitors of the HIV-1 gp41 six-helix bundle formation in the herb extracts and that tannin may inhibit HIV-1 entry by disrupting the gp41 six-helix bundle formation.
Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection

Xinling Wang,Miao Cao,Yanling Wu,Wei Xu,Qian Wang,Tianlei Ying,Lu Lu,Shibo Jiang

DOI: https://doi.org/10.3390/molecules26071964

IF: 4.6

2021-03-31

Molecules

Abstract:Acquired immune deficiency syndrome (AIDS) has prevailed over the last 30 years. Although highly active antiretroviral therapy (HAART) has decreased mortality and efficiently controlled the progression of disease, no vaccine or curative drugs have been approved until now. A viral inactivator is expected to inactivate cell-free virions in the absence of target cells. Previously, we identified a gp120-binding protein, mD1.22, which can inactivate laboratory-adapted HIV-1. In this study, we have found that the gp41 N-terminal heptad repeat (NHR)-binding antibody D5 single-chain variable fragment (scFv) alone cannot inactivate HIV-1 at the high concentration tested. However, D5 scFv in the combination could enhance inactivation activity of mD1.22 against divergent HIV-1 strains, including HIV-1 laboratory-adapted strains, primary HIV-1 isolates, T20- and AZT-resistant strains, and LRA-reactivated virions. Combining mD1.22 and D5 scFv exhibited synergistic effect on inhibition of infection by divergent HIV-1 strains. These results suggest good potential to develop the strategy of combining a gp120-binding protein and a gp41-binding antibody for the treatment of HIV-1 infection.

chemistry, multidisciplinary,biochemistry & molecular biology
HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

Shuwen Liu,Shuai Wu,Shibo Jiang

DOI: https://doi.org/10.2174/138161207779313722

IF: 3.31

2007-01-01

Current Pharmaceutical Design

Abstract:HIV envelope glycoprotein transmembrane subunit gp41 plays a critical role in the fusion between viral and target cell membranes. Upon gp120 binding to CD4 and a coreceptor (CCR5 or CXCR4), gp41 changes its conformation by forming N-helix trimer between N-heptad repeats (NHRs) and then six-helix bundle between the N-trimer and the C-heptad repeats (CHRs). Peptides derived from the NHR and CHR of gp41 extracellular region have demonstrated potent inhibitory activity on the HIV mediated cell fusion. One of these peptides, T-20, became the first success of a new class of anti-HIV agents, named HIV entry inhibitors. However, a relatively long peptide such as T-20 suffers from several limitations including lack of oral bioavailability and high cost of production. Great efforts have been made to develop alternative peptides and proteins with improved anti-HIV-1 activity, increased bioavailability and reduced cost of production. The most promising approach is the development of small molecule HIV entry inhibitors targeting gp41. Any molecule that blocks the process of NHR homotrimerization and the six-helix bundle formation by targeting the gp41 NHR, NHR trimer and CHR may inhibit HIV-mediated membrane fusion. The progress in development of those anti-HIV agents targeting gp41, from polypeptides to small-molecule compounds, is reviewed.
HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMEC

Ambrose Y. Jong,Chu-Hua Wu,Shibo Jiang,Luo Feng,Han-Min Chen,Sheng-He Huang

DOI: https://doi.org/10.1016/j.bbrc.2007.03.100

IF: 3.1

2007-01-01

Biochemical and Biophysical Research Communications

Abstract:Cryptococcus neoformans infection has significantly increased recently, particularly in AIDS patients and immunocompromised individuals. C. neoformans has a predilection to the brain, resulting in devastating meningoencephalitis. We have previously shown the invasion of C. neoformans into the human brain microvascular endothelial cells (HBMEC), which constitute the blood–brain barrier. Here, we demonstrated that C. neoformans invasion of HBMEC was enhanced by HIV-1 gp41 protein. Peptide mapping defined its functional domain around the disulfide-bond linkage of gp41 molecule (a.a. 579–611). Recombinant protein gp41-I90 (a.a. 550–639) can also enhance the binding activity. The enhancement of C. neoformans binding to HBMEC is a strain-independent manner, suggesting that gp41 ectodomain peptide exerts its function directly on HBMEC. Importantly, the enhancement could be observed in mouse animal model. Our results suggest that HIV-1 gp41 ectodomain and C. neoformans may follow a similar invasion mechanism, possibly actin reorganization and/or membrane activation, during pathogen infections on HBMEC.
HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

Chungen Pan,Shuwen Liu,Shibo Jiang

DOI: https://doi.org/10.1016/s0929-6646(10)60029-0

IF: 3.871

2010-01-01

Journal of the Formosan Medical Association

Abstract:Human immunodeficiency virus (HIV)-1 infection is initiated by the binding of gp120 envelope glyco-protein to its cell receptor (CD4) and a coreceptor (CXCR4 or CCR5), followed by a series of conformational changes in the gp41 transmembrane subunit. These changes include insertion of fusion peptide into the target cell membrane and association of C-heptad repeat (CHR) peptide with the N-heptad repeat (NHR) trimer, a pre-hairpin fusion intermediate. A stable six-helix bundle core is then formed, bringing the viral envelope and target cell membrane into close proximity for fusion. Peptides derived from the CHR region, such as T20 and C34, inhibit HIV-1 fusion by interacting with the gp41 fusion intermediate. A number of anti-HIV-1 peptides and small molecule compounds targeting the gp41 NHR-trimer have been identified. By combining HIV fusion/entry inhibitors targeting different sites in the gp41 fusion intermediate, a potent synergistic effect takes place, resulting in a potential new therapeutic strategy for the HIV infection/AIDS. Here, we present an overview of the current development of anti-HIV drugs, particularly those targeting the gp41 fusion intermediate.
Interaction of HIV-1 Gp41 Core with NPF Motif in Epsin

Jinghe Huang,Zhi Qi,Fan Wu,Leszek Kotula,Shibo Jiang,Yinghua Chen

DOI: https://doi.org/10.1074/jbc.m800525200

2008-01-01

Abstract:The human immunodeficiency virus, type 1 (HIV-1), gp41 core plays an important role in fusion between viral and target cell membranes. We previously identified an HIV-1 gp41 core-binding motif HXXNPF (where X is any amino acid residue). In this study, we found that Asn, Pro, and Phe were the key residues for gp41 core binding. There are two NPF motifs in Epsin-1-(470-499), a fragment of Epsin, which is an essential accessory factor of endocytosis that can dock to the plasma membrane by interacting with the lipid. Epsin-1-(470-499) bound significantly to the gp41 core formed by the polypeptide N36(L8)C34 and interacted with the recombinant soluble gp41 containing the core structure. A synthetic peptide containing the Epsin-1-(470-499) sequence could effectively block entry of HIV-1 virions into SupT1 T cells via the endocytosis pathway. These results suggest that interaction between Epsin and the gp41 core, which may be present in the target cell membrane, is probably essential for endocytosis of HIV-1, an alternative pathway of HIV-1 entry into the target cell.
Enhancement of HIV-1 gp41 binding to raji cells by pwm, lps, interferon-γ and interleukin-6

Ying-Hua Chen,Sabine Opitz,Günther Böck,Franz Steindl,Hermann Katinger,Manfred P. Dierich

DOI: https://doi.org/10.1016/0161-5890(93)90449-L

IF: 4.174

1993-01-01

Molecular Immunology

Abstract:Based on our finding that HIV-1 gp41 independently of CD4 can bind to several proteins (gp41 binding protein: GBP) on the human T-cell line H9, B-cell line Raji and monocyte-cell line U937, we examined the effect of mitogens and cytokines on binding of gp41 to H9, Raji and U937 cells. Flow cytometry (FACS) analysis demonstrated that PWM and LPS, IFN-γ and IL-6, but not Con A, IFN-α, -β, -ω and IL-2, could increase gp41 binding to Raji cells. In controls, none of the regulators (IFN-α, -β, -γ, -ω, IL-2, IL-6, Con A, PWM, LPS) could modify the binding potential of H9 and U937 cells. Our data suggest that the expression of HIV-1 binding proteins is subject to regulation by PWM, LPS, IFN-γ and IL-6 in the case of B-cells, while on T-cells and macrophages, the binding proteins may be constitutively expressed.
Development Of Small-Molecule Hiv Entry Inhibitors Specifically Targeting Gp120 Or Gp41

Lu Lu,Fei Yu,Lifeng Cai,Asim K. Debnath,Shibo Jiang

DOI: https://doi.org/10.2174/1568026615666150901114527

2016-01-01

Current Topics in Medicinal Chemistry

Abstract:Human immunodeficiency virus type 1 (HIV-1) envelope (Env) glycoprotein surface subunit gp120 and transmembrane subunit gp41 play important roles in HIV-1 entry, thus serving as key targets for the development of HIV-1 entry inhibitors. T20 peptide (enfuvirtide) is the first U.S. FDA-approved HIV entry inhibitor; however, its clinical application is limited by the lack of oral availability. Here, we have described the structure and function of the HIV-1 gp120 and gp41 subunits and reviewed advancements in the development of small-molecule HIV entry inhibitors specifically targeting these two Env glycoproteins. We then compared the advantages and disadvantages of different categories of HIV entry inhibitor candidates and further predicted the future trend of HIV entry inhibitor development.
HIV-1 Gp41 Ectodomain Enhances Cryptococcus Neoformans Binding to Human Brain Microvascular Endothelial Cells Via Gp41 Core-Induced Membrane Activities

Sheng-He Huang,Chu-Hua Wu,Shibo Jiang,Ingrid Bahner,Albert S. Lossinsky,Ambrose Y. Jong

DOI: https://doi.org/10.1042/bj20110218

IF: 3.766

2011-01-01

Biochemical Journal

Abstract:Cryptococcus neoformans causes life-threatening meningoencephalitis, particularly prevalent in AIDS patients. The interrelationship between C. neoformans and HIV-1 is intriguing, as both pathogens elicit severe neuropathological complications. We have previously demonstrated that the HIV-1 gp41 ectodomain fragments gp41-I33 (amino acids 579-611) and gp41-I90 (amino acids 550-639) can enhance C. neoformans binding to HBMECs (human brain microvascular endothelial cells). Both peptides contain the loop region of gp41. In the present study, we used immunofluorescence microscopy and transmission and scanning electron microscopy to explore the underlying mechanisms. Our findings indicated that both C. neoformans and gp41-I90 up-regulated ICAM-1 (intercellular adhesion molecule 1) on the HBMECs and elicited membrane ruffling on the surface of HBMECs. The HIV-1 gp41 ectodomain could also induce CD44 and β-actin redistribution to the membrane lipid rafts, but it could not enhance PKCα (protein kinase Cα) phosphorylation like C. neoformans. Instead, gp41-I90 was able to induce syncytium formation on HBMECs. The results of the present study suggest HIV-1 gp41-enhanced C. neoformans binding to HBMECs via gp41 core domain-induced membrane activities, revealing a potential mechanism of invasion for this pathogenic fungus into the brain tissues of HIV-1-infected patients.
HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human raji cell mhc class I and II expression by gp41

Ying-Hua Chen,Günther Böck,Rolf Vornhagen,Franz Steindl,Hermann Katinger,Manfred P. Dierich

DOI: https://doi.org/10.1016/0161-5890(94)90092-2

IF: 4.174

1994-01-01

Molecular Immunology

Abstract:Based on our findings, that HIV-1 soluble gp41 could bind to several proteins on the human. T, B and monocyte cells independently of CD4, we examined the effect of HIV-1 soluble gp41 (sgp41; Env amino acids 539–684) on surface expression of MHC I and II, ICAM-1 and CD21 molecules on human Raji cells. Flow cytometry (FACS) analysis demonstrated that sgp41 could selectively enhance MHC class I and II expression on Raji cells, but did not increase expression of other cell surface antigens, such as, CD21 and CD54 (ICAM-1). Soluble gp41 could also enhance MHC class I and II expression on another human B cell line, Bjab. The sgp41-dependent enhancement of the MHC class I and II expression on Raji cells is time- and dose-dependent. The sgp41 enhancement effect on the MHC antigen expression could be inhibited by the gp41-binding proteins of 45, 49 and 62 kD (isolated from Raji-lysate) which could inhibit the sgp41-binding to Raji cells. Interestingly, this sgp41-dependent enhancement of the MHC class I and II expression could also be inhibited by two mAbs to HIV-1 gp41, but not by a third mAb binding to a different site on gp41. These results demonstrate that HIV-1 sgp41 can selectively enhance the human Raji cell MHC class I and II antigen expression and this enhancement effect could be inhibited by the sgp41-binding proteins and anti-gp41 antibodies, and suggest that the sgp41-dependent enhancement is mediated by its binding to Raji membrane proteins of 45, 49 and 62 kD.
Mutations of Gln64 in the HIV-1 Gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the Gp41 Pocket

Xiaowen Yu,Lu,Lifeng Cai,Pei Tong,Suiyi Tan,Peng Zou,Fanxia Meng,Ying-hua Chen,Shibo Jiang

DOI: https://doi.org/10.1128/jvi.05066-11

IF: 6.549

2012-01-01

Journal of Virology

Abstract:ABSTRACT To prove that the peptidic HIV-1 fusion inhibitors containing the pocket-binding domain (PBD) mainly target the hydrophobic pocket in the gp41 N-terminal heptad repeat (NHR), we constructed pseudoviruses by replacement of Q64 in the gp41 pocket region with Ala (Q64A) or Leu (Q64L). These viruses were highly resistant to C34 and CP32M containing the PBD, while they were susceptible to T20 (enfuvirtide) lacking the PBD but containing the GIV-motif-binding domain (GBD) and lipid-binding domain (LBD). They were also sensitive to C52L, which contains the PBD, GBD, and LBD. Those mutations may disrupt the hydrophilic interaction between Q64 in the NHR and N113 in the peptides containing the PBD. This report provides insights into the mechanisms of drug resistance, with implications for the design of novel HIV fusion and entry inhibitors.
HIV-1 Variants with a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors with Pocket- or Membrane-Binding Domain.

Lu,Pei Tong,Xiaowen Yu,Chungen Pan,Peng Zou,Ying-Hua Chen,Shibo Jiang

DOI: https://doi.org/10.1016/j.bbamem.2012.07.020

IF: 4.019

2012-01-01

Biochimica et Biophysica Acta (BBA) - Biomembranes

Abstract:Enfuvirtide (T20), the first FDA-approved peptide HIV fusion/entry inhibitor derived from the HIV-1 gp41 C-terminal heptad-repeat (CHR) domain, is believed to share a target with C34, another well-characterized CHR-peptide, by interacting with the gp41 N-terminal heptad-repeat (NHR) to form six-helix bundle core. However, our previous studies showed that T20 mainly interacts with the N-terminal region of the NHR (N-NHR) and lipid membranes, while C34 mainly binds to the NHR C-terminal pocket region. But so far, no one has shown that C34 can induce drug-resistance mutation in the gp41 pocket region. In this study, we constructed pseudoviruses in which the Ala at the position of 67 in the gp41 pocket region was substituted with Asp, Gly or Ser, respectively, and found that these mutations rendered the viruses highly resistant to C34, but sensitive to T20. The NHR-peptide N36 with mutations of A67 exhibited reduced anti-HIV-1 activity and decreased α-helicity. The stability of six-helix bundle formed by C34 and N36 with A67 mutations was significantly lower than that formed by C34 and N36 with wild-type sequence. The combination of C34 and T20 resulted in potent synergistic anti-HIV-1 effect against the viruses with mutations in either N- or C-terminal region in NHR. These results suggest that C34 with a pocket-binding domain and T20 containing the N-NHR- and membrane-binding domains inhibit HIV-1 fusion by interacting with different target sites and the combinatorial use of C34 and T20 is expected to be effective against HIV-1 variants resistant to HIV fusion inhibitors.
Identification of a Gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein As a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor

Yun Zhu,Lu,Liling Xu,Hengwen Yang,Shibo Jiang,Ying-Hua Chen

DOI: https://doi.org/10.1128/jvi.00644-10

IF: 6.549

2010-01-01

Journal of Virology

Abstract:ABSTRACT Human immunodeficiency virus type 1 (HIV-1) gp41 plays a critical role in the viral fusion process, and its N- and C-terminal heptad repeat domains serve as important targets for developing anti-HIV-1 drugs, like T-20 (generic name, enfuvirtide; brand name, Fuzeon). Here, we conducted a yeast two-hybrid screening on a human bone marrow cDNA library using the recombinant soluble gp41 ectodomain as the bait and identified a novel gp41 core-binding molecule, designated P20. P20 showed no homology with a current HIV fusion inhibitor, T-20, but had sequence homology to a human protein, troponin I type 3 interacting kinase (TNNI3K)-like protein. While it could bind to the six-helix bundle core structure formed by the N- and C-terminal heptad repeats, P20 did not interrupt the formation of the six-helix bundle. P20 was effective in blocking HIV-1 Env-mediated syncytium formation and inhibiting infection by a broad spectrum of HIV-1 strains with distinct subtypes and coreceptor tropism, while it was ineffective against other enveloped viruses, such as vesicular stomatitis virus and influenza A virus. P20 exhibited no significant cytotoxicity to the CD4+ cells that were used for testing antiviral activity. Among the 11 P20 mutants, four analogous peptides with a common motif (WGRLEGRRT) exhibited significantly reduced anti-HIV-1 activity, suggesting that this region is the critical active site of P20. Therefore, this peptide can be used as a lead for developing novel HIV fusion inhibitors and as a probe for studying the membrane-fusogenic mechanism of HIV.

Enhancement of Endocytic Uptake of HIV-1 Virions into CD4-negative Epithelial Cells by HIV-1 Gp41 Via Its Interaction with POB1

Short Communication: in VitroSynergy Between Peptides or Neutralizing Antibodies Targeting the N- and C-Terminal Heptad Repeats of HIV Type 1 Gp41

HIV-1 Glycoprotein 41 Ectodomain Induces Activation of the CD74 Protein-Mediated Extracellular Signal-Regulated Kinase/mitogen-Activated Protein Kinase Pathway to Enhance Viral Infection.

The Mechanism by Which Molecules Containing the HIV Gp41 Core-Binding Motif HXXNPF Inhibit HIV-1 Envelope Glycoprotein-Mediated Syncytium Formation.

Hiv-1 gp 41 ectodomain induces activation of the cd 74-mediated erk / mapk pathway to enhance viral infection

Progress in the structure and function of human immunodeficiency virus type 1 gp41

[1,2,6-Tri-o-galloyl-beta-d-glucopyranose Inhibits Gp41-Mediated HIV Envelope Fusion with Target Cell Membrane].

Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte.

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection

HIV Entry Inhibitors Targeting Gp41: from Polypeptides to Small-Molecule Compounds

HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMEC

HIV-1 Gp41 Fusion Intermediate: a Target for HIV Therapeutics.

Interaction of HIV-1 Gp41 Core with NPF Motif in Epsin

Enhancement of HIV-1 gp41 binding to raji cells by pwm, lps, interferon-γ and interleukin-6

Development Of Small-Molecule Hiv Entry Inhibitors Specifically Targeting Gp120 Or Gp41

HIV-1 Gp41 Ectodomain Enhances Cryptococcus Neoformans Binding to Human Brain Microvascular Endothelial Cells Via Gp41 Core-Induced Membrane Activities

HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human raji cell mhc class I and II expression by gp41

Mutations of Gln64 in the HIV-1 Gp41 N-Terminal Heptad Repeat Render Viruses Resistant to Peptide HIV Fusion Inhibitors Targeting the Gp41 Pocket

HIV-1 Variants with a Single-Point Mutation in the Gp41 Pocket Region Exhibiting Different Susceptibility to HIV Fusion Inhibitors with Pocket- or Membrane-Binding Domain.

Identification of a Gp41 Core-Binding Molecule with Homologous Sequence of Human TNNI3K-Like Protein As a Novel Human Immunodeficiency Virus Type 1 Entry Inhibitor